Autologous Bone Marrow Stem Cells for Chronic Leg Ulcer Treatment in Sickle Cell Disease
Autologous Bone Marrow Stem Cells for Chronic Leg Ulcer Treatment in Sickle Cell Disease
The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow
 stem cell implantation for the treatment of leg ulcer in adult patients with sickle cell
 disease.
Implantation of bone marrow mononuclear cells, including endothelial progenitor cells and
 mesenchymal stromal cells, into leg ulcers has been shown to improve wound healing.

 In the present study the safety and efficacy of autologous bone marrow mononuclear cells
 implantation will be investigated in patients with chronic leg ulcers. Forty cases will be
 enrolled. Improvement in the pain, rate and extent of leg ulcer wound healing as measured by
 change in wound surface area will be evaluated until one year.
Inclusion Criteria:

 -  Stable sickle cell disease patients

 -  Patient hospitalized into the dermatology unit

 -  Patient with an evolutive leg ulcer since more than 1 year

 -  No infection at the time of surgery

 -  Patient competent to give informed consent

 Exclusion Criteria:

 -  Patients with a history of corticosteroids or on active therapy

 -  infection at the limb affected by ulcer

 -  Recurrent painful crises,

 -  Immunosuppressive drug therapy,

 -  Pregnancy,

 -  Presence of neoplastic disease or any other clinical concurrent condition other than
 sickle cell disease that predisposed them to the development of leg ulcer